BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) will present a BioSante cancer vaccine portfolio update at the BIO International Convention, which will take place May 3-6 in Chicago, Illinois.
Stephen M. Simes, BioSante's president & CEO, will speak on Wednesday, May 5, 2010 at 3:15 pm local time. He will provide a status report on BioSante's portfolio of cancer vaccines in clinical development, as well as an update on LibiGel® (testosterone gel) in clinical development for the treatment of female sexual dysfunction.
BioSante's GVAX cancer vaccines currently are in several Phase II clinical trials in various cancer types including vaccines for the treatment of leukemia, breast cancer and pancreatic cancer, and to date have received FDA orphan drug designations for GVAX AML for the treatment of acute myeloid leukemia and GVAX Pancreas for the treatment of pancreatic cancer.
Global leaders gather at the NFCR Summit to drive breakthroughs in cancer care